Innovative stem cell technologies have potential to treat  Alzheimer’s disease.

get effexor xr 100mg prednisone for dog where can i buy a college paper online college lab report example write an essay about computer games dissertation binding services leicester go to site problem solution essays examples medical assistant research paper cheap cialis super force viagra effect erection viagra cheap pills vendita di viagra sai baba problem solving opinion essay writing essay on my goal in life difference between case study and experiment avodart 0 5 mg viagra and alcohol college life essay jane eyre thesis honesty is the best policy short essay pdf cialis online reviews Today, there is no cure for Alzheimer’s disease and dementia. In 2015, dementia affected more than 46.8 million people worldwide, according to Alzheimer’s Disease International, and an estimated 60-80 percent of those patients have Alzheimer’s disease. The number of dementia cases is expected to grow to 74.7 million in 2030 and to reach 131.5 million in 2050. Stemedica International is the only company to leverage three patented, stem cell technologies (itMSCs, itNSCs and related growth factors) for therapies that may be able to address the global, unmet need for treatments of degenerative conditions, including Alzheimer’s disease and vascular dementia. Stemedica International is also exploring opportunities to prevent the condition, based on promising pre-clinical data.

Stemedica International is using cGMP allogeneic stem cells derived from healthy adult volunteers in clinical trials. Manufactured in a licensed facility under cGMP conditions, the company has successfully completed the safety phase of a clinical trial.